Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy
NCT05871606Phase 1Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label trial of nitric oxide in ischemic stroke (6 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Maximum safe dose of iNO for AIS patients at Year 2. Started Apr 2026; status: recruiting.
02
Drugs
nitric oxide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05871606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05871606.